Prothena Corporation plc

NASDAQ PRTA

Data sourced from

and

Download Data

Prothena Corporation plc Accounts Payable Turnover Ratio 5 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -46.11%

Prothena Corporation plc Accounts Payable Turnover Ratio 5 year CAGR is -46.11% for the Trailing 12 Months (TTM) ending March 31, 2024, a -311.19% change year over year. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Prothena Corporation plc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 1.47, a -88.36% change year over year.
Prothena Corporation plc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 12.64, a 18,415.37% change year over year.
Prothena Corporation plc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.07, a -38.37% change year over year.
Prothena Corporation plc Accounts Payable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.11, a 45.29% change year over year.

NASDAQ: PRTA

Prothena Corporation plc

CEO	Dr. Gene G. Kinney Ph.D.
IPO Date	Dec. 21, 2012
Location	Ireland
Headquarters	77 Sir John Rogerson?s Quay, Dublin, Ireland, 2
Employees	173
Sector	Healthcare
Industry	Biotechnology

Description

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Key trends